Alvogen

Pharmaceutical company developing and manufacturing generic, brand and biosimilar products

Based in NJ

🤖

AI Overview

With $1.2M in lobbying spend across 26 quarterly filings, Alvogen is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2018 to 2025.

$1.2M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$75K
2019	$135K
2020	$180K
2021	$180K
2022	$270K
2024	$180K
2025	$135K

Issues Lobbied

Health Issues Tariffs Manufacturing

Lobbying Firms

East End Group, LLC

Lobbyists

Michael Woody Andrew Hawkins Kelly Childress Lange

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Tariffs, Manufacturing

Issues related to development and procurement of influenza antivirals. The re-authorization of the Pandemic and All-Hazards Preparedness Act.

Issues related to development and procurement of influenza antivirals. The re-authorization of the Pandemic and All-Hazards Preparedness Act

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory issues related to development and procurement of pandemic influenza antivirals.

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals.

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals, and the reauthorization of the Pandemic and All-Hazards Preparedness Act.

Section 232 investigation into pharmaceuticals and unfair trade practices.

Buy America legislation, 232 tariff investigation, regulatory incentives for domestic manufacturing.

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals. Issues related to domestic manufacturing and on-shoring pharmaceuticals.